| Price | 215.00p on 27-02-2026 at 19:20:07 |
|---|---|
| Change | -5.00p -2.27% |
| Buy | 219.00p |
| Sell | 211.00p |
| Last Trade: | Unknown 20,000.00 at 220.00p |
| Day's Volume: | 21,341 |
| Last Close: | 215.00p |
| Open: | 220.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.89b |
| VWAP: | 219.56901p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 20,000 | 220.00p | Negotiated Trade |
16:40:36 - 27-Feb-26 |
| Buy* | 14 | 219.00p | SI Trade |
16:07:03 - 27-Feb-26 |
| Sell* | 1 | 213.00p | Ordinary |
15:55:26 - 27-Feb-26 |
| Buy* | 15 | 218.44p | Ordinary |
15:14:04 - 27-Feb-26 |
| Buy* | 2 | 218.84p | Ordinary |
13:17:04 - 27-Feb-26 |
| Sell* | 1,305 | 213.00p | Ordinary |
13:00:27 - 27-Feb-26 |
| Buy* | 4 | 216.00p | SI Trade |
08:05:50 - 27-Feb-26 |
| Unknown* | 21,121 | 220.00p | Negotiated Trade |
16:37:43 - 26-Feb-26 |
| Buy* | 22,021 | 220.00p | Suspected BUY Trade |
16:35:07 - 26-Feb-26 |
| Buy* | 60 | 219.00p | Automatic Execution |
16:08:31 - 26-Feb-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th Feb 2026 8:30 am | RNS | HUTCHMED to Announce 2025 Final Results |
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |